NERVGEN PHARMA CORP (NGEN.CA) Stock Overview
TSX-V:NGEN - CA64082X2032 - Common Stock
NGEN.CA Key Statistics, Chart & Performance
The current stock price of NGEN.CA is 3.32 CAD. In the past month the price decreased by -3.49%. In the past year, price increased by 19.42%.
NGEN.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.91 | 3.71B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.09B | ||
| CRON.CA | CRONOS GROUP INC | 50.57 | 1.36B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.62 | 788.04M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 646.73M | ||
| TSND.CA | TERRASCEND CORP | N/A | 565.50M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 4.7 | 559.49M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 553.51M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 415.13M | ||
| HITI.CA | HIGH TIDE INC | N/A | 402.75M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 23.91 | 388.47M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 310.30M |
Related stock screener links
About NGEN.CA
Company Profile
NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The firm is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The company has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The firm's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
Company Info
NERVGEN PHARMA CORP
112-970 Burrard Street, Unit 1290
Vancouver BRITISH COLUMBIA V7X 1J1 CA
CEO: Paul Brennan
Employees: 10
Phone: 17787311711
NERVGEN PHARMA CORP / NGEN.CA FAQ
What is the stock price of NERVGEN PHARMA CORP today?
The current stock price of NGEN.CA is 3.32 CAD. The price decreased by -6.48% in the last trading session.
What is the ticker symbol for NERVGEN PHARMA CORP stock?
The exchange symbol of NERVGEN PHARMA CORP is NGEN and it is listed on the TSX Venture Exchange exchange.
On which exchange is NGEN.CA stock listed?
NGEN.CA stock is listed on the TSX Venture Exchange exchange.
What is the price forecast or stock price prediction for NERVGEN PHARMA CORP stock?
8 analysts have analysed NGEN.CA and the average price target is 9 CAD. This implies a price increase of 171.13% is expected in the next year compared to the current price of 3.32. Check the NERVGEN PHARMA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NERVGEN PHARMA CORP worth?
NERVGEN PHARMA CORP (NGEN.CA) has a market capitalization of 242.63M CAD. This makes NGEN.CA a Micro Cap stock.
How many employees does NERVGEN PHARMA CORP have?
NERVGEN PHARMA CORP (NGEN.CA) currently has 10 employees.
What are the support and resistance levels for NERVGEN PHARMA CORP (NGEN.CA) stock?
NERVGEN PHARMA CORP (NGEN.CA) has a support level at 2.91 and a resistance level at 3.56. Check the full technical report for a detailed analysis of NGEN.CA support and resistance levels.
Should I buy NERVGEN PHARMA CORP (NGEN.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NGEN.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NGEN.CA, evaluating the profitability, health, valuation and growth aspects
- NERVGEN PHARMA CORP (NGEN.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NERVGEN PHARMA CORP (NGEN.CA) Sales and EPS estimates to see what analysts future expectations are.
- NERVGEN PHARMA CORP (NGEN.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NERVGEN PHARMA CORP (NGEN.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NERVGEN PHARMA CORP (NGEN.CA) Stock Chart to make your own analysis
- NERVGEN PHARMA CORP (NGEN.CA) Latest news and press-releases to stay up to date.
Does NERVGEN PHARMA CORP (NGEN.CA) stock pay dividends?
NGEN.CA does not pay a dividend.
When does NERVGEN PHARMA CORP (NGEN.CA) report earnings?
NERVGEN PHARMA CORP (NGEN.CA) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of NERVGEN PHARMA CORP (NGEN.CA)?
NERVGEN PHARMA CORP (NGEN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).
NGEN.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NGEN.CA. When comparing the yearly performance of all stocks, NGEN.CA is a bad performer in the overall market: 84.14% of all stocks are doing better.
NGEN.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NGEN.CA. NGEN.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NGEN.CA Financial Highlights
Over the last trailing twelve months NGEN.CA reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS increased by 5.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.68% | ||
| ROE | -1843.02% | ||
| Debt/Equity | 0 |
NGEN.CA Forecast & Estimates
8 analysts have analysed NGEN.CA and the average price target is 9 CAD. This implies a price increase of 171.13% is expected in the next year compared to the current price of 3.32.